Interfering with leukocyte rolling - A promising therapeutic approach in inflammatory skin disorders?

Trends in Pharmacological Sciences

Volumn 24, Issue 2, 2003, Pages 49-52

  Boehncke, Wolf H ^a   Schön, Michael P ^b  

^a GOETHE UNIVERSITY   (Germany)

^b OTTO VON GUERICKE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFLAMMATORY AGENT; CDP 850; EFOMYCINE M; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; L SELECTIN; LACTACYSTIN BETA LACTONE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CDP850; PADGEM PROTEIN; PROTEASOME INHIBITOR; PROTEIN ANTIBODY; SELECTIN; UNCLASSIFIED DRUG;

CELL FUNCTION; CELL MIGRATION; CELLULAR DISTRIBUTION; CLINICAL TRIAL; DRUG DESIGN; DRUG EFFECT; DRUG EFFICACY; ENDOTHELIUM CELL; EXTRAVASATION; HUMAN; INFLAMMATION; LEUKOCYTE; LEUKOCYTE ADHERENCE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PROCESSING; PSORIASIS; REVIEW; SKIN; SKIN INFLAMMATION; T LYMPHOCYTE; TRANSCRIPTION REGULATION;

EID: 0037304625     PISSN: 01656147     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-6147(02)00039-1     Document Type: Short Survey

References (18)

1. Springer T.A. Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm. Cell. 76:1994;301-314.
2. von Andrian U.H., Mackay C.R. T-cell function and migration. Two sides of the same coin. New Engl. J. Med. 343:2000;1020-1034.
3. Ley K. Integration of inflammatory signals by rolling neutrophils. Immunol. Rev. 186:2002;8-18.
4. Alon R., et al. The kinetics and shear threshold of transient and rolling interactions of L-selectin with its ligand on leukocytes. Proc. Natl. Acad. Sci. U.S.A. 95:1998;11631-11636.
5. Feizi T. Carbohydrate ligands for the leukocyte-endothelium adhesion molecules, selectins. Results Probl. Cell Differ. 33:2001;201-223.
6. Gerard C., Rollins B.J. Chemokines and disease. Nat. Immunol. 2:2001;108-115.
7. Fuhlbrigge R.C., et al. Cutaneous lymphocyte antigen is a specialized form of PSGL-1 expressed on skin-homing T cells. Nature. 389:1997;978-981.
8. Lowe J.B. Glycosylation in the control of selectin counter-receptor structure and function. Immunol. Rev. 186:2002;19-36.
9. Picker L.J., et al. A unique phenotype of skin-associated lymphocytes in human. Preferential expression of the HECA-452 epitope by benign and malignant T cells at cutaneous sites. Am. J. Pathol. 136:1990;1053-1068.
10. Issekutz A.C., Issekutz T.B. The role of E-selectin, P-selectin, and very late activation antigen-4 in T lymphocyte migration to dermal inflammation. J. Immunol. 168:2002;1934-1939.
11. Slee D.H., et al. Development of potent non-carbohydrate imidazole-based small molecule selectin inhibitors with antiinflammatory activity. J. Med. Chem. 44:2001;2094-2107.
12. De Vleeschauwer M., et al. Design and synthesis of a new sialyl Lewis X mimetic: how selective are the selectin receptors? Bioorg. Med. Chem. Lett. 11:2001;1109-1112.
13. Schön M.P., et al. Efomycine M, a new specific inhibitor of selectin, impairs leukocyte adhesion and alleviates cutaneous inflammation. Nat. Med. 8:2002;366-372.
14. Bushan M., et al. Anti-E-selectin is ineffective in the treatment of psoriasis: a randomized trial. Br. J. Dermatol. 146:2002;824-831.
15. Maly P., et al. The α(1,3)fucosyltransferase Fuc-TVII controls leukocyte trafficking through an essential role in L-, E- and P-selectin ligand biosynthesis. Cell. 86:1996;643-653.
16. Erdmann I., et al. Fucosyltransferase VII-deficient mice with defective E-, P-, and L-selectin ligands show impaired CD4+ and CD8+ T cell migration into the skin, but normal extravasation into visceral organs. J. Immunol. 168:2002;2139-2146.
17. Goldberg A.L., Rock K. Not just research tools - proteasome inhibitors offer therapeutic promise. Nat. Med. 8:2002;338-340.
18. Zollner T.M., et al. Proteasome inhibition reduces superantigen-mediated T cell activation and the severity of psoriasis in a SCID-hu model. J. Clin. Invest. 109:2002;671-678.